Research programme: cancer therapeutics - Eleven Biotherapeutics

Drug Profile

Research programme: cancer therapeutics - Eleven Biotherapeutics

Alternative Names: Armed Antibodies™; NP-1 - Eleven Biotherapeutics; VB 4011; VB 6901; VB-6008; VB-6011; VB-6050; VB-7756; VB1-008; VB1-050; VBX-008; VBX-011; VBX-050

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viventia Biotechnologies
  • Developer Eleven Biotherapeutics
  • Class Antineoplastics; Immunoconjugates; Peptides; Recombinant fusion proteins
  • Mechanism of Action CD44 antigen modulators; Epithelial cell adhesion molecule modulators; Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Mar 2017 Eleven Therapeutics plans to file an IND for Cancer in 2018
  • 21 Sep 2016 Viventia Biotechnologies has been acquired and merged into Eleven Biotherapeutics
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top